ERN ReCONNET Points to Consider for Treating Patients Living with Autoimmune Rheumatic Diseases with Antiviral Therapies and Anti-Sars-cov-2 Antibody Products

R. Talarico,G. A. Ramirez,S. C. Barreira,C. Cardamone,P. Triggianese, S. Aguilera, J. Andersen,T. Avcin, K. Benistan,G. Bertsias,A. Bortoluzzi,C. Bouillot,I. Bulina,G. R. Burmester,S. Callens,P. E. Carreira,R. Cervera,M. Cutolo,L. Damian,E. Della Torre, R. Faria,J. E. Fonseca,I. Galetti, E. Hachulla,L. Iaccarino,S. Jacobsen,N. Khmelinskii, M. Limper,D. Marinello, A. Meyer,G. Moroncini, G. Nagy,M. Olesinska,C. Pamfil,M. Pileckyte, M. Pistello,S. Rednic,C. Richez,V. C. Romao, M. Schneider,S. Sciascia,C. A. Scire,G. Simonini, V. Smith,A. Sulli,C. Tani,S. W. Tas,A. Tincani,M. C. Vonk,M. Tektonidou,M. Mosca

Clinical and Experimental Rheumatology（2023）

引用 0|浏览17

暂无评分

关键词

European Reference Networks,COVID-19,antiviral drugs,monoclonal antibodies,rare and complex diseases,rheumatic and musculoskeletal diseases,connective tissue diseases,patient care,European Commission

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要